First in the world with unique immunotherapy

Else Marit Inderberg and Sebastien Wälchli
Else Marit Inderberg and Sebastien Wälchli

Based on a licence from Else Marit Inderberg and Sebastien Wälchli’s group at The Section of Cell Therapy at Oslo University Hospital, the company Zelluna Immunotherapy is developing natural killer cells that are steered by T cell receptors. The aim is to offer different forms of targeted immunotherapy treatments that do not have to be individually tailored for each patient. Zelluna Immunotherapy receives NOK 83 million from investors and the Research Council of Norway to continue its work on this new form of cancer immunotherapy.

Links:

Read about the new form of cancer immunotherapy, publishen on the inven2 home page:
First in the world with unique immunotherapy (by Elisabeth Kirkeng Andersen)


The Section of Cell Therapy home page

Else Marit Inderberg's CV and publications

Sébastien Wälchli's CV and publications

 

 

 
Page visits: 345